Customizable virus-like particles deliver CRISPR-Cas9 ribonucleoprotein for effective ocular neovascular and Huntington's disease gene therapy

被引:7
作者
Ling, Sikai [1 ,2 ]
Zhang, Xue [1 ]
Dai, Yao [1 ]
Jiang, Zhuofan [1 ]
Zhou, Xujiao [3 ]
Lu, Sicong [1 ]
Qian, Xiaoqing [4 ]
Liu, Jianping [5 ]
Selfjord, Niklas [6 ]
Satir, Tugce Munise [7 ]
Lundin, Anders [7 ]
Touza, Julia Liz [7 ]
Firth, Mike [8 ]
Van Zuydam, Natalie [9 ]
Bilican, Bilada [7 ]
Akcakaya, Pinar [6 ]
Hong, Jiaxu [3 ,10 ]
Cai, Yujia [1 ,11 ,12 ]
机构
[1] Shanghai Jiao Tong Univ, Shanghai Ctr Syst Biomed, Key Lab Syst Biomed, Minist Educ, Shanghai, Peoples R China
[2] BDgene Therapeut, Shanghai, Peoples R China
[3] Fudan Univ, Eye & ENT Hosp, Dept Ophthalmol, State Key Lab Med Neurobiol, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai, Peoples R China
[5] Karolinska Inst, Dept Med Huddinge, Stockholm, Sweden
[6] AstraZeneca, Genome Engn, Discovery Sci, BioPharmaceut R&D, Gothenburg, Sweden
[7] AstraZeneca, Translat Genom, Discovery Sci, BioPharmaceut R&D, Gothenburg, Sweden
[8] AstraZeneca, Data Sci & Quantitat Biol, Discovery Sci, BioPharmaceut R&D, Cambridge, England
[9] Astrazeneca, Data Sci & Quantitat Biol, Discovery Sci, BioPharmaceut R&D, Gothenburg, Sweden
[10] Shanghai Engn Res Ctr Synthet Immunol, Shanghai, Peoples R China
[11] Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, State Key Lab Med Genom, Shanghai, Peoples R China
[12] Shanghai Key Lab Gene Editing & Cell based Immunot, Shanghai, Peoples R China
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
CAS9; RIBONUCLEOPROTEIN; NANOPARTICLE DELIVERY; IMMUNE-RESPONSES; MESSENGER-RNA; EFFICIENT; PROTEIN; BRAIN; TOOLS; CELLS; MODEL;
D O I
10.1038/s41565-024-01851-7
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
In vivo CRISPR gene editing holds enormous potential for various diseases. Ideally, CRISPR delivery should be cell type-specific and time-restricted for optimal efficacy and safety, but customizable methods are lacking. Here we develop a cell-tropism programmable CRISPR-Cas9 ribonucleoprotein delivery system (RIDE) based on virus-like particles. The efficiency of RIDE was comparable to that of adeno-associated virus and lentiviral vectors and higher than lipid nanoparticles. RIDE could be readily reprogrammed to target dendritic cells, T cells and neurons, and significantly ameliorated the disease symptoms in both ocular neovascular and Huntington's disease models via cell-specific gene editing. In addition, RIDE could efficiently edit the huntingtin gene in patients' induced pluripotent stem cell-derived neurons and was tolerated in non-human primates. This study is expected to facilitate the development of in vivo CRISPR therapeutics.
引用
收藏
页码:543 / 553
页数:29
相关论文
共 69 条
[1]   In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes [J].
Agarwal, Shiwani ;
Hanauer, Julia D. S. ;
Frank, Annika M. ;
Riechert, Vanessa ;
Thalheimer, Frederic B. ;
Buchholz, Christian J. .
MOLECULAR THERAPY, 2020, 28 (08) :1783-1794
[2]   Reducing Treatment Burden in AMD [J].
Apte, Rajendra S. .
CELL, 2020, 180 (06) :1033-1033
[3]   Cas-OFFinder: a fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases [J].
Bae, Sangsu ;
Park, Jeongbin ;
Kim, Jin-Soo .
BIOINFORMATICS, 2014, 30 (10) :1473-1475
[4]   Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins [J].
Banskota, Samagya ;
Raguram, Aditya ;
Suh, Susie ;
Du, Samuel W. ;
Davis, Jessie R. ;
Choi, Elliot H. ;
Wang, Xiao ;
Nielsen, Sarah C. ;
Newby, Gregory A. ;
Randolph, Peyton B. ;
Osborn, Mark J. ;
Musunuru, Kiran ;
Palczewski, Krzysztof ;
Liu, David R. .
CELL, 2022, 185 (02) :250-+
[5]   Targeted Knockdown of Overexpressed VEGFA or VEGF164 in Muller cells maintains retinal function by triggering different signaling mechanisms [J].
Becker, Silke ;
Wang, Haibo ;
Simmons, Aaron B. ;
Suwanmanee, Thipparat ;
Stoddard, Gregory J. ;
Kafri, Tal ;
Hartnett, M. Elizabeth .
SCIENTIFIC REPORTS, 2018, 8
[6]   The privileged immunity of immune privileged organs: the case of the eye [J].
Benhar, Inbal ;
London, Anat ;
Schwartz, Michal .
FRONTIERS IN IMMUNOLOGY, 2012, 3
[7]   A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivo [J].
Bestas, Burcu ;
Wimberger, Sandra ;
Degtev, Dmitrii ;
Madsen, Alexandra ;
Rottner, Antje K. ;
Karlsson, Fredrik ;
Naumenko, Sergey ;
Callahan, Megan ;
Touza, Julia Liz ;
Francescatto, Margherita ;
Moller, Carl Ivar ;
Badertscher, Lukas ;
Li, Songyuan ;
Cerboni, Silvia ;
Selfjord, Niklas ;
Ericson, Elke ;
Gordon, Euan ;
Firth, Mike ;
Chylinski, Krzysztof ;
Taheri-Ghahfarokhi, Amir ;
Bohlooly-Y, Mohammad ;
Snowden, Mike ;
Pangalos, Menelaos ;
Nuttall, Barrett ;
Akcakaya, Pinar ;
Sienski, Grzegorz ;
Maresca, Marcello .
NATURE COMMUNICATIONS, 2023, 14 (01)
[8]   Targeted, homology-driven gene insertion in stem cells by ZFN-loaded 'all-in-one' lentiviral vectors [J].
Cai, Yujia ;
Laustsen, Anders ;
Zhou, Yan ;
Sun, Chenglong ;
Anderson, Mads Valdemar ;
Li, Shengting ;
Uldbjerg, Niels ;
Luo, Yonglun ;
Jakobsen, Martin R. ;
Mikkelsen, Jacob Giehm .
ELIFE, 2016, 5
[9]   Targeted genome editing by lentiviral protein transduction of zinc-finger and TAL-effector nucleases [J].
Cai, Yujia ;
Bak, Rasmus O. ;
Mikkelsen, Jacob Giehm .
ELIFE, 2014, 3
[10]   Identification of preexisting adaptive immunity to Cas9 proteins in humans [J].
Charlesworth, Carsten T. ;
Deshpande, Priyanka S. ;
Dever, Daniel P. ;
Camarena, Joab ;
Lemgart, Viktor T. ;
Cromer, M. Kyle ;
Vakulskas, Christopher A. ;
Collingwood, Michael A. ;
Zhang, Liyang ;
Bode, Nicole M. ;
Behlke, Mark A. ;
Dejene, Beruh ;
Cieniewicz, Brandon ;
Romano, Rosa ;
Lesch, Benjamin J. ;
Gomez-Ospina, Natalia ;
Mantri, Sruthi ;
Pavel-Dinu, Mara ;
Weinberg, Kenneth I. ;
Porteus, Matthew H. .
NATURE MEDICINE, 2019, 25 (02) :249-+